Oculis announced it will highlight the progress of its late-stage pipeline, recent development milestones, and ongoing efforts to address significant unmet medical needs at the Eyecelerator and the Association for Research in Vision and Ophthalmology (ARVO) 2026 annual meeting.

The company’s participation comes at a critical juncture, as several of its key programs approach major clinical and regulatory milestones.

“ARVO 2026 comes at a pivotal moment for Oculis, with strong late-stage momentum across our portfolio designed to redefine treatment paradigms in both ophthalmic and neuro-ophthalmic diseases,” said Riad Sherif, MD, Chief Executive Officer of Oculis. “Following the last patient visit completed in April for the DIAMOND phase 3 program, we are fast approaching the pivotal topline results for OCS-01 eye drops in diabetic macular edema, anticipated in June. Furthermore, we continue to advance Privosegtor and Licaminlimab through their respective registrational programs, PIONEER and PREDICT, and believe that our clinical data, recent development progress and regulatory milestones underscore Oculis’ potential to deliver transformative therapies for patients with high unmet medical needs.”

Oculis will begin its ARVO presence with a company update at the Eyecelerator meeting:

  • Presenter: Riad Sherif, MD, CEO
  • Session: Next Generation Retina Therapeutics and Advances in AI Showcase
  • Location: Room 405
  • Date/Time: Friday, May 1, 2:14 PM MDT

The presentation will spotlight advancements across Oculis’ late-stage portfolio, including regulatory progress for Privosegtor, a neuroprotective candidate targeting optic neuropathies, and the completion of the last patient visit in the phase 3 DIAMOND trial evaluating OCS-01 eye drops for diabetic macular edema (DME). Topline results from the DIAMOND study are expected in June 2026.

Oculis-sponsored research on DME will also be featured during the conference:

  • Presentation: Unmet needs in DME management: Latest findings from the DME AWARE Delphi Study
  • Presenter: Professor Baruch D. Kuppermann, MD, PhD, University of California, Irvine
  • Session: Diabetic eye disease 1
  • Location: Bluebird Ballroom 1B
  • Date/Time: Monday, May 4, 12:30 PM MDT

The DME AWARE initiative is a global Delphi study involving 25 leading experts in retina and ophthalmology. It aims to establish consensus on critical gaps in DME management. Interim findings have already highlighted the need for noninvasive treatment options. The final survey results will present additional insights, including the impact of Best Corrected Visual Acuity (BCVA) loss on early intervention decisions and clearer definitions of treatment “poor response” and “non-response.”

Further reinforcing its neuro-ophthalmology focus, Oculis will present new analyses from its phase 2 ACUITY trial of Privosegtor:

  • Presentation: Reduction in retinal ganglion cell loss with Privosegtor in acute optic neuritis
  • Presenter: Professor Martin S. Zinkernagel, MD, PhD, University Hospital of Bern
  • Session: Neurophthalmology
  • Location: Mile High 1A
  • Date/Time: Wednesday, May 6, 2:45 PM MDT

The presentation will feature post-hoc analyses of optical coherence tomography (OCT) scans, demonstrating reduced retinal ganglion cell loss in patients treated with Privosegtor. Additional responder analyses will highlight improvements in low-contrast visual acuity (LCVA), with gains of 15 or 30 letters in some patients.

Privosegtor, a peptoid small molecule capable of crossing both the blood-brain and retinal barriers, is being developed as a potential first-in-class neuroprotective therapy for optic neuritis (ON). The candidate has received both Breakthrough Therapy designation from the FDA and Priority Medicines (PRIME) designation from the European Medicines Agency. Oculis initiated its phase 3 PIONEER-1 trial in ON in the fourth quarter of 2025.